Nutriband Inc. (NTRBW)
| Market Cap | 38.78M -44.7% |
| Revenue (ttm) | 1.80M -4.8% |
| Net Income | -29.90M |
| EPS | -2.51 |
| Shares Out | 12.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 0.3500 |
| Day's Range | n/a |
| 52-Week Range | 0.2500 - 2.9900 |
| Beta | 1.97 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 8, 2026 |
About NTRBW
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
News
Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan will present at the 2026 Georgia Life Sciences...
Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
Nutriband's Active Intelligence subsidiary to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference Company to Meet with Buyers from Walmart Inc, Walgreens,...
Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
ORLANDO, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan has featured on the latest episode of the Jac...
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband has selected the commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit to the FDA for approval per FDA Guidance. Nutriband par...
Nutriband’s Kinesiology Tapes approved for distribution and sale in Costa Rica
Nutriband (NTRB) announced that The Costa Rica Ministry of Health has approved the Company’s line of Kinesiology Tapes for import and Sale. Innomedica CCB, the company’s exclusive distribution partner...
Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica
ORLANDO, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica f...
Nutriband signs exclusive distribution agreement with Innomedica
Nutriband (NTRB) signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products manufactured at its Pocono Pharmaceutical / ...
Nutriband provides summary of annual shareholder meeting
Nutriband (NTRB) has provided an update to shareholders on the key milestones and discussions from this years Annual Shareholders Meeting. Addition of Two New Directors: Allesandro Puddu and Viorica C...
Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
ORLANDO, Fla., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) has provided an update to shareholders on the key milestones and discussions from this years Annual Share...
Nutriband says ‘committed’ to shareholder value as ‘number one focus’
Nutriband (NTRB) announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The letter...
Nutriband CEO Publishes Letter to Shareholders
ORLANDO, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achie...
Nutriband to sell majority stake of Pocono Pharmaceutical for $5M
Nutriband (NTRB) signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical for $5M to EarthVision Bio. Nutriband. Shareholders will retain 10% of the shareholding in Earth…
Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe N...
Nutriband signs LOI with Qvanta Group of companies
Nutriband (NTRB) announced the signing of a non-binding Letter of Intent with the Qvanta Group of Companies. The Qvanta Group comprises Qvanta and its subsidiaries, Qvanta Foundry and Qvanta Capital.
Nutriband provides response to Trump’s Executive Order related to fentanyl
Nutriband (NTRB) provides the following response to the Trump Administration’s Executive Order designating illicit fentanyl and its core precursor chemicals as weapons of mass destruction. “The design...
Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatmen...
Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference
Orlando, Florida--(Newsfile Corp. - November 24, 2025) - Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that its Chairman and Co-Founder, Serguei Melnik will present at NobleCon21 - No...
REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received...
Nutriband announces meeting completed with U.S. FDA for AVERSA FENTANYL
Nutriband (NTRB) announced that it has received final meeting minutes from its recent virtual face-to-face meeting held on September 18, 2025 with the United States Food and Drug Administration, FDA,…
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received...
Nutriband co-founder Gareth Sheridan returns as CEO
Nutriband (NTRB) announced that Company founder, Gareth Sheridan has returned as Company CEO. During the period of August 10 until October 27 , Co-Founder and Chairman, Serguei Melnik had taken…
Nutriband signs agreement with Brand Institute to develop brand for patch
Nutriband (NTRB) announced that through its 4P Therapeutics subsidiary, it has signed an agreement with Brand Institute to develop the worldwide commercial brand name and visual identity for its lead…
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband initiates commercial worldwide brand name development for its lead product, an abuse deterrent transdermal system. Nutriband has partnered with Brand Institute, Inc, the global leader in pha...
Nutriband files provisional patent application for AVERSA technology
Nutriband (NTRB) announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office, USPTO, to further strengthen Nutriband’s intellectual property protection for i...
Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse. ...